Showing results (71-80 of 103) with videos related to
Sort By:
Pageof 11
Blood|July 21, 2011
Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network reportClaudia R Morris, Hae-Young Kim, Felicia Trachtenberg, et al.British Journal of Haematology|November 5, 2013
Validation and reliability of a disease-specific quality of life measure (the TranQol) in adults and children with thalassaemia majorRobert J Klaassen, Nicholas Barrowman, Manuela Merelles-Pulcini, et al.Blood Advances|January 28, 2020
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion supportStella T Chou, Mouaz Alsawas, Ross M Fasano, et al.Blood|January 27, 2012
Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal CohortJanet L Kwiatkowski, Hae-Young Kim, Alexis A Thompson, et al.British Journal of Haematology|July 17, 2009
Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North AmericaMaria G Vogiatzi, Eric A Macklin, Felicia L Trachtenberg, et al.Blood Advances|February 4, 2026
Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological DisordersNora M Gibson, Nhat Thi Duy Nguyen, Sandra Amaral, et al.Frontiers in Physiology|July 24, 2019
The Spectrum of SPTA1-Associated Hereditary SpherocytosisSatheesh Chonat, Mary Risinger, Haripriya Sakthivel, et al.Frontiers in Physiology|November 19, 2019
Corrigendum: The Spectrum of SPTA1-Associated Hereditary SpherocytosisSatheesh Chonat, Mary Risinger, Haripriya Sakthivel, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 29, 2008
Bone disease in thalassemia: a frequent and still unresolved problemMaria G Vogiatzi, Eric A Macklin, Ellen B Fung, et al.Blood Advances|August 26, 2022
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 yearsMohsen S Elalfy, Mona Hamdy, Amal El-Beshlawy, et al.Pageof 11